• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Rituximab improves survival in B-cell lineage acute lymphoblastic leukemia

byNeil D'SouzaandShaidah Deghan, MSc. MD
September 15, 2016
in Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Compared to standard chemotherapy alone, the addition of the rituximab significantly improves event-free survival among adults with CD20-positive, Philadelphia chromosome (Ph)-negative, B-cell precursor Acute Lymphoblastic Leukemia (ALL). Such advantage did not, however, translate into longer overall survival.

2. The addition of rituximab did not result in a significant increase in severe adverse events.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Though tyrosine kinase inhibitors are traditionally used to treat Ph-positive ALL, monoclonal antibodies are being increasingly used to target surface cell antigens (e.g. CD19, CD20, CD22, CD33, CD52). Rituximab is one such agent, showing significant improvement in outcomes when used to treat patients with B-cell non-Hodgkin’s Lymphoma and Burkitt’s mature B-cell lymphoma or leukemia. Though B-cells express CD20 antigen, and prior single center studies have shown benefit when adding rituximab to standard chemotherapy regimens to target such cells, no randomized prospective clinical trial has shown similar findings. As such, this study compared the trial arm of chemotherapy plus rituximab to the control arm of chemotherapy alone, for patients with Ph-negative, B-lineage ALL expressing CD20 antigen.

The trial found a lower incident of relapse in the rituximab arm. However, this did not translate into a significant difference in overall survival between the two arms. In addition, there were similar rates of adverse events between the chemotherapy plus rituximab and chemotherapy alone arms. The major strength of this study is attributed to the multi-centre, prospective randomized controlled nature of the trial, with the largest cohort of study participants to date. Limitations of this study are related to the multiple comparisons required to generate secondary endpoints and completing post-hoc analyses, and a age cohort limited to 18-59 years of age.

Click to read the study, published today in NEJM

Relevant Reading: Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia

RELATED REPORTS

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

Biosimilar drugs undergo rigorous clinical testing and yield comparable outcomes to biologics

Belimumab after rituximab reduces risk for severe flare in systemic lupus erythematosus

In-Depth [randomized controlled trial]: Given prior single centre studies showing improved outcomes of adding rituximab to chemotherapy compared to chemotherapy alone, this study tested this comparison in the context of a prospective, randomized controlled trial. Adults aged 18-59 years old were accrued across 59 French and 9 Swiss sites between May 2006 and April 2014, all of which were CD20-positive, Ph-negative. Patients were randomized to receive chemotherapy either with or without rituximab, the latter of which was given through all treatment phases (total of 16-18 infusions). The primary endpoint was event-free survival. Events were defined as: failure of complete remission induction, relapse, and death.

There were a total of 209 patients enrolled in the study between the dates noted above, with 105 in the rituximab group and 104 in the chemotherapy alone group. The median percentage of CD20-positive blasts was 66% (range – 20-100%) between the two groups, and was evenly balanced. The median follow up was 30 months, with a total of 101 patients (48%) having at least one event: 44 (42%) patients in the rituximab group and 57 (55%) in the control group. Patients in the rituximab group had longer event-free compared to those in the chemotherapy alone group (HR 0.66; 95%CI 0.45-0.98; p = 0.04). The difference in survival was mostly attributed to the lower relapse rate in the rituximab group, with a subdistributon hazard ratio of 0.52 (95%CI 0.31-0.89; p = 0.02). There was no difference in overall survival between the two groups (HR 0.7; 95%CI 0.46-1.07; p = 0.1). Overall, there were 246 severe adverse events, however, there were no significant difference between the two groups (p = 0.72).

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: acute lymphoblastic leukemiarituximab
Previous Post

Association between transcatheter aortic valve replacement and subsequent infective endocarditis and death

Next Post

Herpes zoster subunit vaccine safe and highly effective in adults over 70: The ZOE-70 trial

RelatedReports

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia
StudyGraphics

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

April 8, 2022
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Oncology

Biosimilar drugs undergo rigorous clinical testing and yield comparable outcomes to biologics

February 22, 2022
Quick Take: Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
Chronic Disease

Belimumab after rituximab reduces risk for severe flare in systemic lupus erythematosus

November 15, 2021
#VisualAbstract Lenalidomide in combination with R-CHOP is effective in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma
StudyGraphics

#VisualAbstract Lenalidomide in combination with R-CHOP is effective in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma

November 12, 2021
Next Post
Herpes zoster vaccine not cost-effective for 50 year-old adults

Herpes zoster subunit vaccine safe and highly effective in adults over 70: The ZOE-70 trial

No difference in mortality for intensive versus standard reduction in blood pressure in intracerebral hemorrhage: The ATACH-2 trial

No difference in mortality for intensive versus standard reduction in blood pressure in intracerebral hemorrhage: The ATACH-2 trial

Added tension to transcervical catheters does not expedite delivery

Added tension to transcervical catheters does not expedite delivery

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Daily disposable contact lenses may lower risk for Acanthamoeba keratitis
  • Vitamin D deficiency may be associated with sleep disorders in children
  • Prasinezumab therapy does not affect Parkinson’s Disease progression
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.